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Abstract 17 
Understanding the bioactivation mechanisms to predict toxic metabolites is critical for risk 18 
assessment of phenolic endocrine-disrupting chemicals (EDCs). One mechanism involves ipso-19 
substitution, which may contribute to the total turnover of phenolic EDCs, yet the detailed 20 
mechanism and its relationship with other mechanisms are unknown. We used density functional 21 
theory to investigate the P450-catalyzed ipso-substitution mechanism of the prominent 22 
xenoestrogen bisphenol A. The ipso-substitution proceeds via H-abstraction from bisphenol A by 23 
Compound I, followed by essentially barrierless OH-rebound onto the ipso-position forming a 24 
quinol, which can spontaneously decompose into the carbocation and hydroquinone. This 25 
carbocation can further evolve into the highly estrogenic hydroxylated and dimer-type metabolites. 26 
The H-abstraction/OH-rebound reaction mechanism has been verified as a general reaction mode 27 
for many other phenolic EDCs, such as bisphenol analogues, alkylphenols and chlorophenols. The 28 
identified mechanism enables us to effectively distinguish between type I (eliminating-substituent 29 
as anion) and type II (eliminating-substituent as cation) ipso-substitution in various phenolic 30 
EDCs. We envision that the identified pathways will be applicable for prediction of metabolites 31 
from phenolic EDCs whose fate is affected by this alternative type of P450 reactivity, and 32 
accordingly enable the screening of these metabolites for endocrine-disrupting activity.  33 
 34 
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Introduction 38 
Biotransformation plays a critical role in determining the toxicity of xenobiotics in organisms and 39 
has drawn considerable attention as a basis for environmental risk assessment.1,2 40 
Biotransformation of environmental endocrine-disrupting chemicals (EDCs) is one such 41 
example.3,4 Accurate risk assessment of EDCs requires consideration of bioactivation via 42 
biotransformation processes, especially by human cytochrome P450 enzymes (P450), since 43 
neglecting these metabolic pathways may lead to undervaluation of their adverse effects on human 44 
health, although the metabolism of phenolic chemicals by P450 is minor compared with the 45 
glucuronidation pathway under normal circumstances.3,4 P450 enzymes are a superfamily of 46 
monooxygenases distributed through all kingdoms of life, and are responsible for most phase-I 47 
biotransformation reactions.5-9 Some of these conversions produce metabolites that are much more 48 
toxic than their parent compounds, an important example being phenolic EDCs.10 Phenolic EDCs 49 
such as bisphenol analogues, alkylphenols and chlorophenols, are ubiquitous in the environment 50 
as widely used industrial chemicals, with associated high risk of environmental exposure.10 Among 51 
these, although bisphenol A (BPA) has traditionally been considered a weak environmental 52 
xenoestrogen because of its much lower binding affinity to the estrogen receptor than that of 53 
estradiol,11 the biotransformation largely affects the endocrine disrupting activity of BPA.4 54 
As shown in Scheme 1, conjugation with the phase II glucuronide enzyme is the predominant 55 
metabolic pathway of BPA in humans (more than 90% of all BPA metabolites), which represents 56 
a major detoxification pathway;12 however, BPA is also metabolized by human P450 to form 57 
ortho-OH-BPA via hydroxylation of the aromatic ring,12 to form hydroxycumyl alcohol (HCA), 58 
isopropenylphenol (IPP), and hydroquinone (HQ) via an ipso-substitution mechanism,13 and to 59 
form a dimer-type metabolite 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP) whose 60 
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formation may involve IPP reacting with isopropenylphenol radical.14,15 In vitro assays have 61 
shown that HCA can exhibit 100-fold higher estrogen activity than BPA (concentrations of 10−5 62 
to 10−10 M),13 while MBP can be 1000-fold more potent (concentrations of 10−5 to 10−9 M).14 63 
Although the ipso-substitution pathway of the P450-catalyzed metabolic activation of BPA is most 64 
likely a minor pathway under most circumstances, such strong endocrine-disrupting activity of the 65 
metabolites makes this pathway important to the overall environmental risk assessment, especially 66 
under conditions where glucuronidation is impaired by e.g. other compounds or for genetic or 67 
developmental reasons. For example, human fetal livers show little or no glucuronidation16 and in 68 
contrast to rodents express significant levels of P450 leading to metabolizing many xenobiotic 69 
compounds even at the prenatal stage.17,18 thus P450-catalyzed metabolic activation is more likely 70 
relatively more significant in the fetus.3,19,20    71 
 Scheme 1. Major Metabolic Pathways of Bisphenol A  72 
 73 
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Formation of metabolites via ipso-substitution constitutes about 20% of the competing ortho-80 
OH-BPA formation via traditional aromatic hydroxylation by P450,13 i.e. ipso-substitution is 81 
quantitatively important in competition with the traditional aromatic hydroxylation of phenolic 82 
EDCs. Oxidation of diverse p-substituted phenols by rat liver P450 has been found to result in 83 
elimination of the substituents, including -NO2, -CH2OH, -COCH3, -COPh, -COOH, -F, -Cl, and 84 
–Br.21 Accordingly, ipso-substitution can be categorized into two types depending on the group 85 
eliminated from the quinol intermediate.21,22 As shown in Scheme 2, type I ipso-substitution 86 
implies that the substituent eliminates as an anion with formation of a quinone, whereas in type II 87 
ipso-substitution the eliminating group is a cation, leading to the formation of a hydroquinone.21  88 
However, during oxidation of 4-n-nonylphenol, estrone, estradiol etc. by P450, ipso-addition 89 
quinol was formed without C-C bond cleavage.23,24 Therefore, the ipso-substitution, ipso-addition, 90 
as well as the above-mentioned aromatic hydroxylation mechanisms compete under various 91 
conditions as relevant pathways, and understanding these mechanisms at the molecular level seems 92 
necessary to access the environmental toxicity and fate of phenolic EDCs. However, the active 93 
species of P450, the iron(IV)-oxo heme cation radical Compound I (Cpd I), responsible for P450-94 
catalyzed oxidations in all P450 isoenzymes, is short-lived and one of the most potent oxidants in 95 
nature,25,26 and thus several details of its catalytic action are inaccessible by standard experimental 96 
methods. Specially, two possible pathways for P450-catalyzed ipso-substitution via a quinol 97 
intermediate should be distinguished; one involveing initial formation of a phenoxy radical and 98 
the other involving the formation of an epoxide via O-addition.27-29  99 
Analysis of enzyme mechanisms using computational chemistry may identify with semi-100 
quantitative accuracy the electronic structure features governing reactivity.30-38 Density functional 101 
theory (DFT) has been used to study many P450-catalyzed oxygenation reactions including 102 
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hydroxylation of C-H bonds, epoxidation of C=C bonds, oxidation of aromatic rings, oxidation of 103 
heteroatoms etc.33 The main goal of this work is to show how DFT can be used to elucidate the 104 
full molecular mechanism of the P450-dependent metabolism of phenolic EDCs and to identify 105 
how and when environmentally related ipso-substitution, and formation of the very estrogenic 106 
dimer-type metabolites can occur. BPA was used to obtain the full mechanistic picture because of 107 
its prominence in the environment,39,40 with rich experimental data of its P450-catalyzed 108 
metabolism13,14 for validation of the computationally obtained mechanisms. The work was 109 
extended to also study the P450-catalyzed biotransformation mechanisms of several other widely-110 
used phenolic EDCs, such as bisphenol analogues, alkylphenols and chlorophenols. The 111 
fundamental electronic drivers that govern ipso-addition vs. ipso-substitution and type I vs. type 112 
II substitute elimination were identified, directly relevant for screening P450-catalyzed 113 
biotransformation of many emerging environmental phenolic EDCs.  114 
 115 
Scheme 2. Proposed ipso-Substitution Mechanisms of P450-Catalyzed Substituent Eliminationa 116 
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a The reactive position is defined as the ipso-position; R represents the elimination substituent. 118 
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Computational Methodology 121 
DFT Calculations with Cpd I of P450. As is common practice,29,41-43 the six-coordinate tri-122 
radicaloid ferryl complex Fe4+O2-(C20N4H12)
-1(SH)-1 was used to model the enzymatic active site 123 
of Cpd I of P450. Cpd I of P450 exists in two close-lying electronic states, a high-spin (HS) quartet 124 
state and a low-spin (LS) doublet state.33,44 All geometries on both the LS and HS routes were 125 
optimized with unrestricted DFT using the B3LYP hybrid density functional45,46 in combination 126 
with the LAN2DZ basis set47 on iron and 6–31G on other atoms (denoted BSI). B3LYP was chosen 127 
because it can reproduce measured kinetic isotope effects for P450-catalyzed reactions,48 electron 128 
paramagnetic resonance parameters for penta-coordinated heme in P450 enzyme,49 generate 129 
geometries consistent with crystal structures,50 and show qualitatively accurate relative energies 130 
vs. benchmark CASSCF calculations.51 Intrinsic reaction coordinate (IRC) calculations were 131 
performed to verify the rate-determining transition states connecting the reactants and 132 
intermediates on the potential energy surface (Figure S1-S22 in the Supporting Information). 133 
Please note that the basis-set superposition error (BSSE) has been reported to be very small for 134 
reactant complexes of P450-catalyzed oxidation reactions,52 but they may affect the relative 135 
energies of very large vs. small substrates and thus we did not include these minor contributions 136 
to the energies in the following as our substrates are similar in size and type. 137 
In order to evaluate broadly the sensitivity of the reaction mechanism toward the choice of 138 
density functional, in addition to the B3LYP energies (Table S1 in the Supporting Information), 139 
we performed unrestricted single-point calculations with other hybrid, local, and non-hybrid 140 
functionals, i.e. TPSSh,53,54 B3PW91,46,55 BLYP45,56 MPW1PW91,57 and M06L58 using the 141 
B3LYP/BSI optimized geometries for the P450-catalyzed metabolic mechanisms of BPA (Table 142 
S2 in the Supporting Information). The same qualitative picture was obtained with all of the 143 
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functionals, and we therefore focused in the following on the B3LYP results. To test the basis set 144 
effect on geometry optimization, the molecular species involved in the initial H-abstraction from 145 
the phenolic group as well as in the O-addition to the aromatic ring of BPA were optimized at the 146 
B3LYP/BSI** level, producing few geometrical and energetic discrepancies as compared with the 147 
results obtained at the B3LYP/BSI level (detailed data in Table S3 and Figure S23 in the 148 
Supporting Information). Hence the basis set BSI was used for geometry optimizations throughout 149 
the remaining work. 150 
Analytical frequency calculations were used to ensure that there was no imaginary frequency 151 
for any ground state, and only one imaginary frequency for all transition states. The vibrational 152 
frequencies were also used to calculate the zero-point energy (ZPE) and thermal and entropic 153 
corrections to the free energy at 298.15 K and 101.325 kPa. More accurate energies were obtained 154 
using single-point calculations with the SDD59 basis set on iron and the 6–311++G** basis set for 155 
all other atoms (denoted BSII). Bulk polarity effects were evaluated by the PCM solvation model60 156 
using chlorobenzene with a dielectric constant of 5.6 at the B3LYP/BSI level; this dielectric 157 
constant provides a good estimate of the polarization caused by the dipoles of the protein pocket 158 
near the axial cysteine.61 We also evaluated the bulk polarity effect using the SMD solvation 159 
model62 for the P450-catalyzed mechanisms of BPA; the H-abstraction and O-addition steps 160 
occurred with only slightly higher energies (Table S4 in the Supporting Information). In addition, 161 
we evaluated PCM energies using cyclohexane (ε=2.0), 1-bromopropane (ε=8.0), ethanol (ε=24.9), 162 
and acetonitrile (ε=35.7). Except for a minor difference in energy for the oxidation of BPA, the 163 
same qualitative picture was obtained throughout (Table S5 in the Supporting Information). 164 
Dispersion interactions were considered by performing single-point energy calculations with the 165 
B3LYP-D3/BSI level since B3LYP itself does not include dispersion by design.63 The relative free 166 
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energies of the P450 oxidation reactions shown below were estimated by combining B3LYP/BSII 167 
single-point energies with PCM solvation and dispersion corrections, as well as Gibbs free energy 168 
corrections from optimizations at the BSI level, unless pointed out specifically. 169 
The cluster approach of studying the reaction mechanism treats the catalytic active site of the 170 
enzyme by including key surrounding amino acids and treating all these interactions fully quantum 171 
mechanically.38 BPA is mainly catalyzed by P450 isoforms 3A4 and 3A5,13 and therefore we used 172 
the P450 3A4 crystal structure (PDB code: 1W0G)64 to produce a larger model of the active site. 173 
As shown in Figure S24 in the Supporting Information, the Cpd I model is the same in the large 174 
and small model, whereas six important second-shell residues, ARG105, ILE301, THR309 and 175 
ALA370 and the peptide chain of ALA305−GLY306 have been included in the large model, with 176 
key central atoms locked in their crystallographic positions to maintain the protein scaffold 177 
packing, steric effects, and hydrogen bond geometries. The large model is charge-neutral and 178 
contains 138 atoms, and the reaction mechanism was investigated for both the HS and LS states. 179 
The geometry optimization, more accurate single-point calculations, evaluation of the bulk polarity 180 
effects, and dispersion interactions were all performed in the same way for both the large and small 181 
models. The results are discussed in detail in the Supporting Information, where all energies are 182 
compiled in Tables S1-S31. Importantly, we conclude that the small and large models are in good 183 
agreement on the preferred pathways (Figure S25 in the Supporting Information), probably 184 
because the main energy effects and electronic reorganizations occur near the iron-oxygen moiety. 185 
We thus performed an extended series of calculations based on the small model as discussed below. 186 
Reaction Energy Calculations for the Decomposition of Quinol Intermediates. All 187 
geometries for the decomposition reactions of various ipso-addition quinol intermediates from 188 
P450-catalyzed ipso-position metabolism were optimized at the B3LYP/6-31G** level in water 189 
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solution (ε=78.4) with PCM. Then based on the optimized structures, single-point calculations 190 
were performed in PCM water solution with D3 dispersion corrections at the B3LYP/6-311++G** 191 
level. The reported reaction free energies for decomposition of quinol intermediates are described 192 
by PCM//B3LYP/6-311++G** with water solution and D3 dispersion corrections, as well as free 193 
energy corrections from B3LYP/6-31G** geometry optimizations. 194 
All calculations of this work were carried out with the Gaussian 09 D.01 program package.65 195 
 196 
Results and Discussion 197 
Reaction Mechanisms of P450-Catalyzed Bisphenol A 198 
H-abstraction vs. O-addition. Figure 1 shows two computed competitive reaction 199 
mechanisms of BPA catalyzed by P450, one involving initial H-abstraction from the phenolic 200 
group, and the other involving initial O-addition to the π-system of the aromatic ring. As is 201 
common in P450 reactions,33 both the HS and LS pathways are available due to the near-degenerate 202 
states of Cpd I. The reactions start from reactant complexes (4,2RC), in which the H-atom of the 203 
phenolic group of BPA interacts with the iron-oxo moiety of Cpd I. Then, 4,2RC may go through 204 
H-abstraction transition states 4,2TSH with formation of the intermediate complexes (
4,2IH) 205 
involving iron-hydroxo species and the phenoxy radical of BPA. The HS transition state 4TSH 206 
appears slightly later on the reaction coordinate than its LS counterpart 2TSH, with BPA−O···H 207 
and H···O−Fe distances of 1.211 vs. 1.207 Å and 1.203 vs. 1.212 Å, respectively. These H-208 
abstraction transition states are characterized by almost linear O…H…O configurations as well as 209 
large imaginary frequencies (HS: i1521 cm-1; LS: i1569 cm-1). Cpd I is a potent H-atom abstractor 210 
toward the phenolic group, with a H-abstraction barrier of only 0.4/0.3 kcal/mol for the HS/LS 211 
state, similar to the minor H-abstraction barriers obtained for the phenolic group of paracetamol29 212 
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and the amino group of anilines42, yet much lower than the H-abstraction barriers obtained from 213 
C−H hydroxylation.41,52,66 In addition, the formed complex intermediates (4,2IH) are stable, with 214 
exothermic reaction energies of -8.0/-7.4 kcal/mol for the HS/LS state. Note that dispersion effects 215 
lower the H-abstraction barriers by a substantial 2.5 kcal/mol, a magnitude consistent with 216 
previous findings for P450 reactions.67  217 
Another possible reaction path starting from 4,2RC is the addition of the oxo group of Cpd I 218 
onto the unsubstituted aromatic ring of BPA via C-O bond-forming transition states 4,2TSO, which 219 
produce tetrahedral intermediates. As shown in Figure 1, compared with the LS species, TSO in 220 
the HS state is more advanced (shorter O…C bond) with a higher degree of aromatic activation. 221 
The calculated barriers for O-addition at the ortho-position (4,2TSOo) and meta-position (
4,2TSOm) 222 
are 17.5/14.5 and 19.9/17.1 kcal/mol, respectively, on the HS/LS state surfaces. Comparison of 223 
the barriers of the H-abstraction and O-addition steps shows clearly that the H-abstraction reaction 224 
is much more favorable. Therefore, we focused on the H-abstraction pathway in the following 225 
sections. 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
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 242 
Figure 1. Free energy profile of BPA catalyzed by Cpd I of P450, along with the optimized 243 
geometries of the key reaction species in the HS and LS states. Free energies (kcal/mol) are relative 244 
to the quartet reactant complex 4RC at the B3LYP/BSII//BSI level including solvation (ε=5.6) and 245 
dispersion corrections (no parentheses), and without dispersion (in parentheses). Geometrical 246 
parameters (lengths in Å and angles in degrees) are shown as the HS [LS] state. 247 
 248 
OH Radical Rebound Mechanism. For the H-abstraction pathway, formation of the 249 
intermediate complex (4,2IMH) is followed by rebound of the phenoxy radical onto the iron-250 
hydroxo species. This occurs via formation of covalent bonds at the ipso-, ortho- or meta-carbon 251 
of the aromatic ring of BPA to yield corresponding addition quinol intermediates IMipso, IMortho or 252 
IMmeta. As shown in Figure 1, all the rebound steps are essentially barrierless in the LS state, while 253 
they proceed with significant barriers of 7.8-17.4 kcal/mol on the HS surface. The rebound 254 
reactions at the ipso- and ortho-carbon are exothermic for both the HS and LS pathways, with 255 
reaction energies of -31.6/-29.5 and -30.3/-32.7 kcal/mol, respectively, while the rebound reactions 256 
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at the meta-carbon are endothermic (+4.1/+8.1 kcal/mol). Importantly, the thermodynamically 257 
unfavorable rebound reactions associated with this mechanism can explain the lack of 258 
experimental detection of the hydroxylation product of the meta-position during P450-dependent 259 
metabolism of BPA.13 Note that the HS rebound barriers are significantly larger than the initial H-260 
abstraction barriers, implying that 4Cpd I is a sluggish oxidant and unlikely to play a key role. 261 
Thus, OH recombination with the phenyl ring of BPA only occurs via the LS potential energy 262 
surface. Accordingly, OH radical rebound will proceed under thermodynamic control, and the 263 
reaction energy difference between formation of IMortho of -32.7 kcal/mol and IMipso of -29.5 264 
kcal/mol for the LS state of about 3.2 kcal/mol, favors IMortho formation but also translates into a 265 
lower fraction of IMipso formed. This is in accordance with the observation that metabolites formed 266 
via ipso-substitution constitute approximately 20% of the products of the traditional aromatic 267 
hydroxylation pathway of P450.13  268 
Decomposition Reaction of the Quinol Intermediate (IMipso) of BPA. Hydroquinone, 269 
isopropenylphenol (IPP), and hydroxycumyl alcohol (HCA) were detected as metabolites upon C-270 
C bond scission via ipso-substitution in experiments of the P450-catalyzed degradation of 271 
BPA,13,68 which means that the ipso-metabolism reaction of BPA does not stop in the quinol form. 272 
In order to understand the complete mechanistic picture, we need to establish the nature of the 273 
quinol intermediate decomposition. As mentioned above, there are two types of substituent 274 
elimination from the quinol intermediate. While hydroquinone has been detected in the 275 
experiments of oxidation of BPA by P450,13,68-70 quinone is also easily transformed to 276 
hydroquinone upon NADPH-induced reduction in rat liver microsomes.21 Therefore, it is difficult 277 
to conclude whether the decomposition of the ipso-addition quinol intermediate (IMipso) proceeds 278 
via type I or type II elimination based on the available experimental data. 279 
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 280 
Table 1. Computed Aqueous-Phase Free Energies (ΔG) (kcal/mol) for the Decomposition 281 
Reactions of Quinol of BPA 282 
Condition Elimination Type 
ΔG 
(kcal/mol) 
Neutralization Type I 
O
OH OH
O
OH
OH +
+
 
82.1 
Neutralization Type II 
O
OH OH
+
O
OH
OH +
 
11.1 
Deprotonation Type I 
O
O
O
OH
O- +
OH
 
21.8 
Protonation Type II 
+
OH
OH OH
+
OH
OH
OH +
 
-30.7 
 283 
As shown in Table 1, the heterolytic decomposition of IMipso may proceed charge-neutrally 284 
or after protonation or deprotonation in water solution. The computations suggest that the charge-285 
neutral decompositions of IMipso leading to a carbocation (type II ipso-substitution) or carbanion 286 
intermediate (type I ipso-substitution) have reaction energies of +11.1 kcal/mol and +82.1 kcal/mol, 287 
respectively. The decomposition of IMipso after deprotonation (type I ipso-substitution) is 288 
endothermic by +21.8 kcal/mol. Thus, the most feasible pathway is decomposition after 289 
protonation with production of the carbocationic intermediate and hydroquinone (type II ipso-290 
substitution) with a reaction energy of -30.7 kcal/mol, which supports that the quinol intermediate 291 
generated in the P450 enzyme pocket can readily dissociate from the pocket and decompose in a 292 
nonenzymatic environment after protonation.  293 
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The carbocationic intermediate can react to produce IPP by fast proton transfer to a hydroxyl 294 
ion with a reaction energy of -48.7 kcal/mol, or into HCA by absorbing the hydroxyl ion with a 295 
reaction energy of -44.0 kcal/mol (using the same method of calculations as for the decomposition 296 
of quinols). This mechanism would explain the puzzling observation that no quinol of BPA has 297 
ever been detected as an ipso-addition metabolite:13,68-70 From our reaction diagrams, it is an 298 
unstable intermediate that quickly collapses to the product. 299 
MBP Formation. A dimer-type metabolite MBP has been shown to exhibit the highest 300 
estrogen activity among all BPA metabolites, and thus we investigated also the MBP formation 301 
mechanism. First, we examined the feasibility of the previously suggested  radical pathway of 302 
MBP formation; this reaction occurs between the isopropenylphenol radical formed by oxidative 303 
cleavage of the carbon–phenyl bond, and IPP, as supported by the disappearance of the mass peak 304 
of MBP when a radical scavenger was added to the incubation system.14 However, as shown in 305 
Table S31 in the Supporting Information, the cleavage reactions of the carbon–phenyl bond of 306 
BPA and the phenoxy radical of BPA in the enzymatic environment are both highly endothermic, 307 
and thus the radical pathway seems unfavorable. According to LC/MS/MS investigation, the 308 
metabolite of BPA gave a negative mass peak at [M–H]- 267 in LC/MS and a single daughter ion 309 
at m/z 133 on MS/MS analysis, corresponding to MBP and IPP, respectively.14 Alternatively, the 310 
dimer-type structure of MBP triggers cationic polymerization, by which the carbocation reacts 311 
with IPP, with both reactants originating from the ipso-substitution pathway, initiating 312 
polymerization and generation of MBP, as shown in eq 1: 313 
OH
OH OH
OH OH
+ +
+
+ H2O
ΔG = -47.7 kcal/mol 
 314 
(1) 
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The obtained reaction energy of −47.7 kcal/mol provides a notable driving force for this cationic 315 
polymerization pathway to form MBP (using the same method of calculation as for the 316 
decomposition of quinols). The P450-catalyzed ipso-substitution suggested above proceeds 317 
through the radical pathway involving H-abstraction from BPA to produce a phenoxy radical, 318 
which would explain why adding a radical scavenger to the incubation system prevents MBP 319 
formation during the experiment. 320 
 321 
The Reaction Patterns of P450-Catalyzed ipso-Position Metabolism 322 
Initial Rate-Determining Step for the Production of ipso-Addition Quinol Intermediates. 323 
In order to study the detailed reaction mechanism and to verify the initial rate-determining step for 324 
ipso-position metabolism, we studied several other widely-used phenolic EDCs distributed in the 325 
environment such as bisphenol analogues, alkylphenols and chlorophenols with available in vitro 326 
or in vivo assay data on the P450 metabolism.3,14,15,21,23,71 As shown in Table 2, these phenolic 327 
EDCs include bisphenol F (BPF), bisphenol B (BPB), tetrabromobisphenol A (TBBPA), 328 
dimethylbisphenol A (DMBPA), bisphenol AF (BPAF), bisphenol Z (BPZ), 4-n-nonylphenol 329 
(NP1), p-hydroxybenzoic acid (PHBA), p-cresol (PC), and p-chlorophenol (PCP). The relative 330 
energies of the H-abstraction from the phenolic group as well as O-addition at the aromatic ortho-331 
carbon position on the LS potential energy surface are listed in Table 2. The barriers of H-332 
abstraction (0.4-3.1 kcal/mol) are much lower than that for O-addition (14.2-21.0 kcal/mol) for all 333 
phenolic EDCs, i.e. the initial step involves H-abstraction by Cpd I from the phenolic group 334 
leading to an intermediate complex consisting of an iron-hydroxo group and a phenoxy radical. 335 
Within the intermediate complex, as in the reaction of BPA catalyzed by P450, the OH rebounds 336 
onto both the ipso- and ortho-carbon to form the hydroxylation intermediates with markedly 337 
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exothermic reaction energies (-36.3 to -16.5 kcal/mol). The OH rebound barriers for the HS 338 
pathway (4.4-13.5 kcal/mol) are much higher than the initial H-abstraction barriers (see details in 339 
Table S9 in the Supporting Information), while the OH rebound on the LS pathway is essentially 340 
barrier-free. Therefore, we suggest that the P450-catalyzed ipso-position metabolism of these 341 
diverse phenolic EDCs follows the same reaction mode as displayed in Figure 1 of BPA, i.e. via 342 
H-abstraction followed by an essentially barrierless OH rebound onto the ipso-carbon to produce 343 
the corresponding ipso-addition quinol intermediate mainly via the LS state.  344 
As shown in Table 2, compared with the thermodynamic data on OH rebound onto the ortho-345 
positions, the rebound reactions onto the ipso-positions are 2.3 and 2.6 kcal/mol more favorable 346 
for PCP and NP1, respectively, but 0.7-9.1 kcal/mol less favorable for all other phenolic EDCs. 347 
Although the driving force for ortho-addition relative to ipso-addition is much larger for PBHA, 348 
BPAF and TBBPA, the obtained energy difference of 6-9 kcal/mol may still translate into a lower 349 
fraction of the ipso-addition quinol intermediates. Regardless of the external factors, we conclude 350 
that the P450-catalyzed ipso-position metabolism competes with ortho-position metabolism in the 351 
LS state under thermodynamic control. This is consistent with the experiments, in which ipso-352 
substitution/addition metabolites of all studied phenolic EDCs studied in this work were observed 353 
in the presence of P450, such as 4-hexafluorohydroxyisopropilidene-phenol from BPAF, and 2,6-354 
dibromo-4-(2-hydroxypropane-2-yl) phenol from TBBPA, which may be produced by the addition 355 
of hydroxyl ion to the carbocations as the ipso-substitution products, as well as 4-nonyl-4-hydroxy-356 
cyclohexa-2,5-dienone produced from 4-NP1 as the ipso-addition product. Until now, there are no 357 
reported ratios of ipso-addition vs. ortho-addition products for most phenolic EDCs. However, the 358 
calculated energy difference between ipso-addition and ortho-addition can be used as a probe for 359 
predicting the relative importance of these two pathways.  360 
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 361 
Table 2. Relative Free Energies (kcal/mol) for P450-catalyzed ipso-Position Metabolism of 362 
Phenolic EDCs via the LS state 363 
Phenolic EDCs 2TSH 2TSOo 2IMH 2IMipso 2IMortho ΔGgap 
Bisphenol 
Analogues 
BPF 
OHOH  
2.1 16.6 -6.6 -32.3 -33.0 0.7 
BPB 
OHOH  
1.2 14.2 -6.5 -30.5 -34.1 3.6 
TBBPA 
OHOH
Br
Br
Br
Br  
0.4 19.9 -6.7 -30.1 -36.3 6.2 
DMBPA 
OHOH  
0.4 15.4 -7.8 -30.3 -33.7 3.4 
BPAF 
OHOH
CF3F3C
 
3.1 19.5 0.6 -17.0 -26.1 9.1 
BPZ 
OHOH  
1.8 16.1 -6.0 -29.0 -32.3 3.3 
Alkylphenols 
NP1 
OH
C9H19
 
1.6 18.2 -5.9 -32.4 -29.8 -2.6 
PHBA 
OH
COOH
 
3.0 21.0 1.6 -16.5 -23.6 7.1 
PC 
OH
CH3
 
2.7 17.8 -6.8 -28.8 -30.6 1.8 
Chlorophenols PCP 
OH
Cl
 
2.8 20.1 -2.9 -29.0 -26.7 -2.3 
 364 
Decomposition Reaction Mechanisms of Diverse Quinol Intermediates. Experimental 365 
work on P450-catalyzed phenolic EDCs has shown that ipso-substitution prior to ipso-addition 366 
does not always occur.21,23,24,69 However, the reason why some phenolic EDCs are stopped at the 367 
ipso-addition step is unknown. It is also difficult to determine which type of elimination (type I or 368 
type II) occurs during ipso-substitution due to the complex biological redox environment. We 369 
focused on the decomposition mechanisms of the diverse ipso-addition quinol intermediates 370 
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derived from the diverse phenolic EDCs described above with the available experimental 371 
information,21,69 but excluded TBBPA and BPZ, for which our attempts to locate the quinol 372 
intermediates after protonation give fragmental type II products directly. The thermodynamic data 373 
for the decomposition of quinol intermediates in all possible pathways were evaluated and the most 374 
favorable decomposition paths via type II and type I ipso-substitution are shown in Figure 2.  375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
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 384 
 385 
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 388 
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 391 
 392 
 393 
 394 
 395 
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 398 
 399 
Figure 2. Computed free energies (kcal/mol) for the decomposition reactions of diverse ipso-400 
addition quinols along the favorable pathways: (left) type II substitution with the hydride ion 401 
affinity (HIA, kcal/mol) of the formed carbocation; (right) type I substitution. a R represents the 402 
elimination substituent.  403 
 404 
As shown in Figure 2, for all bisphenol analogues and alkylphenols except for PHBA, the 405 
decomposition of the formed ipso-addition quinols after protonation with formation of carbocation 406 
and hydroquinone (type II substitution) is the most favorable pathway. The decomposition 407 
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reactions for the ipso-addition quinols from PC and NP1 are distinctly endothermic, which is fully 408 
in line with experimental observations of the P450-catalyzed conversion of these two alkylphenols 409 
showing only ipso-addition quinols were produced without detecting any ipso-substitution 410 
products.21,23,69 However, for other bisphenol analogues and alkylphenols, the decomposition of 411 
the formed ipso-addition quinols after protonation can proceed, leading to C-C bond cleavage with 412 
significant exothermic energies. It is found that the P450-catalyzed ipso-substitution products are 413 
obtained from the ipso-addition quinols when the carbon at the benzylic position contains one or 414 
more alkyl branches. More alkyl branches stabilize the carbocation via inductive and 415 
hyperconjugative effects; this results in the spontaneous decomposition of the formed ipso-416 
addition quinols after protonation. The hydride ion affinity (HIA) can be used for comparing the 417 
carbocation stability of dissimilar structures directly, defined according to eq (2):72  418 
                 RH ⟶ R+ +  H−      ΔH0  =  HIA                                                                                   (2) 419 
The HIA obtained at the B3LYP/6-311++G** level using frequency analysis at 298.15 K and 1 420 
atm pressure are listed in the lower left of Figure 2. The experimental HIA is available for CH3
+ 421 
(312 kcal/mol),72 the same as the computed HIA of 312 kcal/mol, which supports the reliability of 422 
the computational method. The reaction free energies of decomposition of the quinol intermediates 423 
generally increase with increasing HIA of the formed carbocations (r2 = 0.95, ΔG = 1.4HIA + 424 
245.5). This pattern indicates that the HIA values are useful for preliminary evaluation of the 425 
decomposition free energies of the ipso-addition quinols produced from bisphenol analogues and 426 
alkylphenols with associated formation of a carbocation and a hydroquinone (type II substitution). 427 
For quinol intermediates with electronegative substituents, such as -Cl and -COOH, as shown 428 
in Figure 2, there are two possible pathways for substituent elimination from quinol with the 429 
formation of an anion and a quinone (type I ipso-substitution): 1) elimination of the substituent 430 
 21 
after deprotonation with the formation of an anion and quinone; 2) involving the prior intra-431 
molecular H-arrangement from OH to the electronegative substituents to produce the 432 
corresponding inorganic acid and quinone neutrally. The charge-neutral intra-molecular H-433 
arrangement pathway with formation of the inorganic acid and quinone is more favorable for 434 
decomposition of quinol intermediates with electronegative substituents; in this case the inorganic 435 
acid can dissociate into an anion. The pathway we have obtained for type I ipso-substitution 436 
extends the formal definition of type I ipso-substitution in P450 chemistry. In particular, the 437 
elimination of -COOH from quinol after deprotonation is not feasible because it is endothermic, 438 
while the exothermic elimination of -COOH during the intra-molecular H-arrangement route is 439 
favorable. This is in accordance with the experimental observation that PHBA can be subject to 440 
ipso-substitution when the reaction is catalyzed by P450.21 441 
 442 
Environmental Implications 443 
Identification of EDCs is one of the most important goals of environmental chemical hazard 444 
screening, which has come a long way in developing useful test assays and mechanism-based 445 
screening techniques.10 Many synthetic compounds released into the environment may be readily 446 
transformed, especially by P450 enzymes, into metabolites exhibiting much higher endocrine- 447 
disrupting activity than their parent compounds. Knowledge of detailed metabolic mechanisms 448 
gives insight into the bioactivation. Accordingly, it is critical in environmental risk assessment to 449 
understand metabolic pathways and to have effective tools for predicting the fate of metabolites. 450 
Methods that analyze and predict the metabolic fate of molecules thrive within the field of 451 
medicinal chemistry,73 but not so much within environmental sciences despite the similarity of 452 
involved tools. In medicinal chemistry, many drugs require P450-mediated bioactivation to elicit 453 
their pharmacological effect via metabolites that can be characterized in relatively high 454 
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concentrations. In contrast, environmental pollutants such as EDCs and their metabolites normally 455 
occur in trace amounts while still important at these levels, and thus identification of their 456 
biotransformation products seems more difficult, and mechanism-based methods to provide 457 
putative metabolites efficiently are of interest. Experimental methods often require expensive 458 
equipment, expertise, running costs and time, which may reduce their applicability when screening 459 
large libraries of compounds. Thus, there is substantial interest in the development of fast, accurate 460 
computational tools that can predict metabolism with higher throughput and lower cost. These 461 
computational tools should: (i) predict the site of metabolism and (ii) predict the metabolite 462 
structure from these sites.74 463 
The present work shows how detailed DFT investigations of metabolic pathways can 464 
rationalize the formation of metabolites resulting from the P450-catalyzed reactions of diverse 465 
environmental phenolic EDCs such as bisphenol analogues, alkylphenols and chlorophenols, 466 
thereby achieving these two tasks, as particularly emphasized for one of the prominent phenolic 467 
EDCs, BPA. The barrier for the most favorable H-abstraction/OH-rebound mechanism involving 468 
both the ipso- and ortho-position hydroxylation is one of the lowest reported barriers, as far as we 469 
know. The H-abstraction/OH-rebound reaction with formation of the quinol intermediate seems to 470 
be a general reaction mechanism for phenolic EDCs, as shown by studying a diverse group of such 471 
compounds in this work. In case of the ipso-addition quinol intermediate, we can distinguish type 472 
II vs. type I ipso-substitutions based on thermodynamic data, and ipso-substitution vs. ipso-473 
addition based on the stability of the eliminating carbocation by both qualitative and quantitative 474 
analysis. Notably, the formation mechanism of the highly estrogenic metabolites HCA and dimer-475 
type MBP, which arises from oxidation of BPA catalyzed by P450, has been revealed in detail. 476 
Our results show that both metabolites originate from a carbocationic intermediate produced in the 477 
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ipso-substitution pathway. This pathway gives insight into the potentially important bioactivation 478 
of many other alternatives to BPA whose metabolic mechanisms remain unidentified, in particular 479 
under conditions where P450-catalyzed metabolism is important relative to glucuronidation (e.g. 480 
if this pathway is inhibited or genetically or otherwise down-regulated, e.g. in the fetus). However, 481 
even when non-P450 pathways dominates by 10-, 100- or even 1000-fold, the ipso-position 482 
metabolites may still contribute to toxicity due to their correspondingly higher potency. 483 
The hydroxylated metabolites of many emerging phenolic pollutants, such as OH-PBDEs and 484 
OH-PCBs, have been reported to be even stronger EDCs than their precursors,75,76 and based on 485 
their similar molecular structures we speculate that they may involve products from the ipso-486 
substitution/addition pathway catalyzed by P450, which has thus far largely been neglected. 487 
Recently, the biotransformation of sulfonamide antibiotics in the environment has been reported 488 
to proceed via the ipso-substitution pathway.77 Therefore, ipso-substitution seems to be a much 489 
more common and, even at low turnover, more important toxification pathway than previously 490 
thought for a wide variety of persistent pollutants. Our study has identified the detailed electronic 491 
structure changes and transition states probably involved in these processes, as well as provided 492 
simple tools for determining the relative importance of these pathways based on thermodynamic 493 
considerations that we envision will be valuable for determining the environmental toxicity and 494 
fate of emerging phenolic EDCs. 495 
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